Caroline Y. Kuo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Caroline Y. Kuo has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Donald Barry Kohn
University of California, Los Angeles, Los Angeles, California, UNITED STATES
4 shared publications Joseph D. Long
Division of Allergy & Immunology, Department of Pediatrics, David Geffen School of Medicine at the University of California, Los Angeles, 10833 Le Conte, MDCC 12-430, Los Angeles, CA 90095, USA
3 shared publicationsAlok V. Joglekar
Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA
2 shared publicationsDonald B. Kohn
Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, USA
2 shared publications- Megan D. Hoban
Department of Microbiology, Immunology, and Molecular Genetics, Eli &Edythe Broad Center of Regenerative Medicine &Stem Cell Research, University of California, Los Angeles, Los Angeles, California, USA
2 shared publications Morton J. Cowan
University of California San Francisco Benioff Children’s Hospital, San Francisco, CA
2 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (6)
STAT1 gain-of-function variant in a previously healthy patient with disseminated Mycobacterium genavense infection
Signal transducer and activator of transcription 1 (STAT1) defects present with diverse clinical phenotypes. We describe an unusual genotype/phenotype: disseminated mycobacterial infection without chronic mucocutaneous candidiasis in the context of a pathogenic STAT1 gain-of-function variant (p.Lys388Glu). To our knowledge, this is the first report of such a case.
- 25 August 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (6)
Open AccessSTAT1 gain-of-function variant in a previously healthy patient with disseminated Mycobacterium genavense infection
Signal transducer and activator of transcription 1 (STAT1) defects present with diverse clinical phenotypes. We describe an unusual genotype/phenotype: disseminated mycobacterial infection without chronic mucocutaneous candidiasis in the context of a pathogenic STAT1 gain-of-function variant (p.Lys388Glu). To our knowledge, this is the first report of such a case.
- 22 April 2025
- Published by Oxford University Press (OUP) in The Journal of Immunology
CD40 ligand: the essential link in B/T cell collaboration and immune activation
This Pillars of Immunology article is a commentary on 2 pivotal articles that shaped the CD40-CD40L field – “Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM,” written by U. Korthäuer, D. Graf, H.W. Mages, F. Brière, M. Padayachee, S. Malcolm, A.G. Ugazio, L.D. Notarangelo, R.J. Levinsky, and R.A. Kroczek, and published in Nature, in 1993. https://www.nature.com/articles/361539a0; and “CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM” written by J.P. DiSanto, J.Y. Bonnefoy, J.F. Gauchatt, A. Fischer, and G. de Saint Basile, and published in Nature, in 1993. https://www.nature.com/articles/361541a0.
- 22 April 2025
- Published by Oxford University Press (OUP) in The Journal of Immunology
CD40 ligand: the essential link in B/T cell collaboration and immune activation
This Pillars of Immunology article is a commentary on 2 pivotal articles that shaped the CD40-CD40L field – “Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM,” written by U. Korthäuer, D. Graf, H.W. Mages, F. Brière, M. Padayachee, S. Malcolm, A.G. Ugazio, L.D. Notarangelo, R.J. Levinsky, and R.A. Kroczek, and published in Nature, in 1993. https://www.nature.com/articles/361539a0; and “CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM” written by J.P. DiSanto, J.Y. Bonnefoy, J.F. Gauchatt, A. Fischer, and G. de Saint Basile, and published in Nature, in 1993. https://www.nature.com/articles/361541a0.
- 19 June 2024
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 44 (7) , 1-4
Effective Management of XLA Associated Enteropathy with Vedolizumab Monotherapy
- 19 June 2024
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 44 (7) , 1-4
Effective Management of XLA Associated Enteropathy with Vedolizumab Monotherapy
- Open Access
- 18 August 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (7) , 685-705
Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC
Adenosine deaminase (ADA) deficiency causes ∼13% of cases of severe combined immune deficiency (SCID). Treatments include enzyme replacement therapy (ERT), hematopoietic cell transplant (HCT), and gene therapy (GT). We evaluated 131 patients with ADA-SCID diagnosed between 1982 and 2017 who were enrolled in the Primary Immune Deficiency Treatment Consortium SCID studies. Baseline clinical, immunologic, genetic characteristics, and treatment outcomes were analyzed. First definitive cellular therapy (FDCT) included 56 receiving HCT without preceding ERT (HCT); 31 HCT preceded by ERT (ERT-HCT); and 33 GT preceded by ERT (ERT-GT). Five-year event-free survival (EFS, alive, no need for further ERT or cellular therapy) was 49.5% (HCT), 73% (ERT-HCT), and 75.3% (ERT-GT; P < .01). Overall survival (OS) at 5 years after FDCT was 72.5% (HCT), 79.6% (ERT-HCT), and 100% (ERT-GT; P = .01). Five-year OS was superior for patients undergoing HCT at <3.5 months of age (91.6% vs 68% if ≥3.5 months, P = .02). Active infection at the time of HCT (regardless of ERT) decreased 5-year EFS (33.1% vs 68.2%, P < .01) and OS (64.7% vs 82.3%, P = .02). Five-year EFS (90.5%) and OS (100%) were best for matched sibling and matched family donors (MSD/MFD). For patients treated after the year 2000 and without active infection at the time of FDCT, no difference in 5-year EFS or OS was found between HCT using a variety of transplant approaches and ERT-GT. This suggests alternative donor HCT may be considered when MSD/MFD HCT and GT are not available, particularly when newborn screening identifies patients with ADA-SCID soon after birth and before the onset of infections. This trial was registered at www.clinicaltrials.gov as #NCT01186913 and #NCT01346150.
- 18 August 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (7) , 685-705
Open AccessOutcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC
Adenosine deaminase (ADA) deficiency causes ∼13% of cases of severe combined immune deficiency (SCID). Treatments include enzyme replacement therapy (ERT), hematopoietic cell transplant (HCT), and gene therapy (GT). We evaluated 131 patients with ADA-SCID diagnosed between 1982 and 2017 who were enrolled in the Primary Immune Deficiency Treatment Consortium SCID studies. Baseline clinical, immunologic, genetic characteristics, and treatment outcomes were analyzed. First definitive cellular therapy (FDCT) included 56 receiving HCT without preceding ERT (HCT); 31 HCT preceded by ERT (ERT-HCT); and 33 GT preceded by ERT (ERT-GT). Five-year event-free survival (EFS, alive, no need for further ERT or cellular therapy) was 49.5% (HCT), 73% (ERT-HCT), and 75.3% (ERT-GT; P < .01). Overall survival (OS) at 5 years after FDCT was 72.5% (HCT), 79.6% (ERT-HCT), and 100% (ERT-GT; P = .01). Five-year OS was superior for patients undergoing HCT at <3.5 months of age (91.6% vs 68% if ≥3.5 months, P = .02). Active infection at the time of HCT (regardless of ERT) decreased 5-year EFS (33.1% vs 68.2%, P < .01) and OS (64.7% vs 82.3%, P = .02). Five-year EFS (90.5%) and OS (100%) were best for matched sibling and matched family donors (MSD/MFD). For patients treated after the year 2000 and without active infection at the time of FDCT, no difference in 5-year EFS or OS was found between HCT using a variety of transplant approaches and ERT-GT. This suggests alternative donor HCT may be considered when MSD/MFD HCT and GT are not available, particularly when newborn screening identifies patients with ADA-SCID soon after birth and before the onset of infections. This trial was registered at www.clinicaltrials.gov as #NCT01186913 and #NCT01346150.
- 28 June 2022
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 36 (4) , 829-851
Genes as Medicine
- 28 June 2022
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 36 (4) , 829-851
Genes as Medicine
- Open Access
- 3 February 2022
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 25, 101305
Ocular findings associated with FADD deficiency resemble familial exudative vitreoretinopathy
- 3 February 2022
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 25, 101305
Open AccessOcular findings associated with FADD deficiency resemble familial exudative vitreoretinopathy
- Open Access
- 14 December 2021
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 27, 505-516
A comparison of DNA repair pathways to achieve a site-specific gene modification of the Bruton's tyrosine kinase gene
- 14 December 2021
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 27, 505-516
Open AccessA comparison of DNA repair pathways to achieve a site-specific gene modification of the Bruton's tyrosine kinase gene
- 1 May 2021
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 126 (5) , 449-450
Hematopoietic stem cell transplant for the treatment of adenosine deaminase–deficient severe combined immune deficiency
- 1 May 2021
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 126 (5) , 449-450
Hematopoietic stem cell transplant for the treatment of adenosine deaminase–deficient severe combined immune deficiency
- 19 November 2020
- Published by Taylor & Francis in AIDS Care
- Vol. 33 (7) , 858-866
Power to participants: methodological and ethical reflections from a decade of adolescent advisory groups in South Africa
Whilst the HIV response has made significant progress in increasing representation of adults affected by HIV, the meaningful inclusion of children and adolescents has lagged. But this may be a pivotal moment of change. We report on a decade of conducting adolescent advisory groups in South Africa, to reflect on youth advisory processes. Data was collected from 2008 to 2018 from adolescent advisors (n = 60) and researchers (n = 25), and included feedback sessions, social media, anonymous “post-boxes” and interviews. Findings include the value of adolescent involvement in multiple stages of research co-creation and engagement in policy processes, the need for a safe environment and supporting adolescents living in extreme vulnerability. We also discuss the reconfiguring of power and personal relationships, and logistical and financial needs of adolescent advisory groups. Findings suggest that adolescent co-creation of research is feasible, even with very vulnerable adolescents, although ethical considerations need to be carefully addressed. Benefits include increased methodological rigour, enhanced adolescent acceptability of research and the recalibration of research dynamics for the empowerment of their target beneficiaries. Future studies could benefit from meaningfully involving adolescents through youth advisory groups.
- 19 November 2020
- Published by Taylor & Francis in AIDS Care
- Vol. 33 (7) , 858-866
Power to participants: methodological and ethical reflections from a decade of adolescent advisory groups in South Africa
Whilst the HIV response has made significant progress in increasing representation of adults affected by HIV, the meaningful inclusion of children and adolescents has lagged. But this may be a pivotal moment of change. We report on a decade of conducting adolescent advisory groups in South Africa, to reflect on youth advisory processes. Data was collected from 2008 to 2018 from adolescent advisors (n = 60) and researchers (n = 25), and included feedback sessions, social media, anonymous “post-boxes” and interviews. Findings include the value of adolescent involvement in multiple stages of research co-creation and engagement in policy processes, the need for a safe environment and supporting adolescents living in extreme vulnerability. We also discuss the reconfiguring of power and personal relationships, and logistical and financial needs of adolescent advisory groups. Findings suggest that adolescent co-creation of research is feasible, even with very vulnerable adolescents, although ethical considerations need to be carefully addressed. Benefits include increased methodological rigour, enhanced adolescent acceptability of research and the recalibration of research dynamics for the empowerment of their target beneficiaries. Future studies could benefit from meaningfully involving adolescents through youth advisory groups.
- 5 November 2020
- Published by Springer Nature
- p. 487-490
MHC Class II, Deficiency of